Organophosphonates

Publication Title: 
European Cells & Materials

Covalent modifications of titanium with small molecules known to promote human osteoblast maturation are especially attractive in developing superior biomaterials. An important step in securing competent bone formation at implant sites is promoting the formation of mature osteoblasts, either from committed pre-osteoblasts or from their mesenchymal progenitors.

Author(s): 
Mansell, Jason P.
Brown, Judith
Knapp, Jonathan G.
Faul, Charl F. J.
Blom, Ashley W.
Publication Title: 
AIDS patient care and STDs

In 2010, the iPrEx study demonstrated efficacy of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) pre-exposure prophylaxis (PrEP) in reducing HIV acquisition among men who have sex with men. Adherence to study product was critical for PrEP efficacy, and varied considerably, with FTC/TDF detection rates highest in the United States.

Author(s): 
Gilmore, Hailey J.
Liu, Albert
Koester, Kimberly Ann
Amico, K. Rivet
McMahan, Vanessa
Goicochea, Pedro
Vargas, Lorena
Lubensky, David
Buchbinder, Susan
Grant, Robert
Publication Title: 
Psychopharmacology

RATIONALE: A recent in-vitro study demonstrated that the potent disulfide reducing agent, DL-dithiothreitol (DTT), may alter the structural stability of the GABA(B) receptor, probably inactivating the disulfide bonds between four cysteine residues located in the GABA(B1(a)) receptor structure. OBJECTIVES: The present study was designed to evaluate whether DTT treatment was capable of antagonizing some behavioral effects of pharmacological stimulation of the GABA(B) receptor.

Author(s): 
Carai, Mauro A. M.
Vacca, Giovanni
Serra, Salvatore
Colombo, Giancarlo
Froestl, Wolfgang
Gessa, Gian Luigi
Publication Title: 
Antiviral Therapy

BACKGROUND: Bone mineral density decreases with antiretroviral therapy (ART) initiation, although the pathogenesis, including the role of tenofovir (TDF), is unclear. This study assessed changes in bone-turnover markers, osteoprotegerin (OPG), soluble receptor activator for nuclear factor-κβ ligand (sRANKL), and inflammation in subjects initiating TDF- versus non-TDF-containing regimens, and determined the relationship between bone turnover, OPG/sRANKL and inflammation.

Author(s): 
Brown, Todd T.
Ross, Allison C.
Storer, Norma
Labbato, Danielle
McComsey, Grace A.
Publication Title: 
Antiviral Therapy

BACKGROUND: Lipoatrophy modestly improves when the thymidine analogue nucleoside reverse transcriptase inhibitor (tNRTI) is removed. In vitro, uridine (NucleomaxX(®); Pharma Nord, Vojens, Denmark) reversed tNRTI mitochondrial toxicity. METHODS: All patients had lipoatrophy on a tNRTI-containing regimen with HIV RNA<400 copies/ml. A randomized 48-week study switched patients from tNRTI to tenofovir (TDF) or added uridine (continuing tNRTI).

Author(s): 
McComsey, Grace A.
O'Riordan, MaryAnn
Choi, Julia
Libutti, Daniel
Rowe, David
Storer, Norma
Harrill, Danielle
Gerschenson, Mariana
Subscribe to RSS - Organophosphonates